Author: Dr. Zandra Klippel, Global Product Head, Multiple Myeloma, Sanofi At the ASCO 2024 conference, Dr. Zandra Klippel the Global…
Browsing: Multiple Myeloma
… Multiple myeloma, an incurable cancer affecting plasma cells in the bone marrow, continues to challenge the medical community. The…
ASH Groundbreaking Trials and Therapies Transform Multiple Myeloma Treatment The recent American Society of Hematology (ASH) meeting showcased significant advancements…
The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with…
Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews Below) On February 20th, 2024…
Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study titled Outcomes of Vdpace for…
Asya Nina Varshavsky-Yanovsky, MD, PhD, serves as an Assistant Professor within the Department of Bone Marrow Transplant and Cellular Therapies.…
At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina, discussed a multicenter study focusing…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at the Sylvester Comprehensive Cancer Center,…
By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI in Rocky Mountain Cancer Centers,…
By. Katja Weisel, MD Date: October 25. 2023 In the world of multiple myeloma research, Dr. Katja Weisel, MD, stands…
KEY TAKEAWAYS Bispecific antibodies, such as talquetamab, represent a transformative shift in cancer treatment, offering the potential to target two…
Refractory multiple myeloma remains a significant challenge in the field of oncology, necessitating innovative therapeutic strategies. Mezigdomide, a novel oral…
Majid Jaberi-Douraki, PhD from Kansas State University, and Shahzad Raza, MD from the Cleveland Clinic, conducted a study to evaluate…
Majid Jaberi-Douraki, PhD -Kansas State University and Shahzad Raza, MD – Cleveland Clinic This study analyzed data from the FDA…
by: Niels Van de Donk, MD, Amsterdam UMC Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, continues to show…
Monique Hartley-Brown, MD, MMSc, from Dana-Farber Cancer Institute, conducted a significant clinical study called “SUCCESSOR-2” that focused on the treatment…
“Correction: The mPFS is not 34 months but 34%.” Carolina Schinke, MD from the UASM Health provided insights into the…
In this study, the researchers evaluated the use of standard of care (SOC) ciltacabtagene autoleucel in a patient population and…
Idecabtagene Vicleucel Shows Effectiveness and Safety in High-Risk Multiple Myeloma Patients Krina Patel MD By Krina Patel, MD, MSc So…
REGN5458: A Trial for Relapsed/Refractory Multiple Myeloma a BCMAxCD3 Bispecific Antibody Naresh Bumma MD By Naresh Bumma, MD – Ohio…
2023 ASH BCMA & Multiple Myeloma Updates with Slides by: Lisa Lee, MD – Assistant Professor — Division of Hematology-Oncology, Department…
What ASH abstracts stood out to you most in multiple myeloma? By Lisa X. Lee, MD from UCI Health At…
MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with…
iFrame is not supported! MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP…
MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with…
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated…
Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated…
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How…
iFrame is not supported! Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is…
Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…
iFrame is not supported! MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can…
MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do…
GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with…
iFrame is not supported! GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can…
GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with…
TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from…
iFrame is not supported! Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and…
Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help…
iFrame is not supported! Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do…
Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma…
iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen…
iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen…
iFrame is not supported! Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD…
Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD How can Mezigdomide (CC-92480)…
iFrame is not supported! Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the…
Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and…
This immersive practice guide offers “how to†methods and day-to-day strategies via faculty commentary and a review of data and…